ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Novo Nordisk A/S securities between May 7, 2025, and July 28, 2025, of the September 30, 2025, deadline to become lead plaintiffs in a class action lawsuit [1][2]. Group 1: Class Action Details - A class action lawsuit has been filed against Novo Nordisk, alleging that the company provided misleading statements about its growth potential while concealing material adverse facts [4]. - Investors who purchased securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2]. - The lawsuit claims that Novo Nordisk overstated its potential in the GLP-1 market and the likelihood of patients switching to its branded alternatives, leading to investor damages when the true information was revealed [4]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [3]. - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [3]. - The firm was ranked No. 1 for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [3].